A PYMNTS Company

J&J gets approval to buy Synthes, as EC accepts its commitment to sell trauma business

By  |  April 19, 2012

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The European Commission has approved Johnson & Johnson’s proposed acquisition of Synthes, subject to J&J selling their trauma business. Johnson & Johnson had submitted commitments to selling their European trauma device business, given the Commission’s findings of J&J and Synthes’ market shares and the reluctance of surgeons in switching suppliers.

    Following an investigation into the market for orthopedic medical devices, the Commission found that strong competitors for spine, shoulder replacement and cranio-maxillofacial devices would remain after the transaction.

    Full content: EC Press Release

     

    Related content: Analyzing Medical Device Mergers

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.